Department of Medical Oncology, First floor, Charing Cross Hospital, Fulham Palace Road, London, UK.
Future Oncol. 2009 Aug;5(6):779-84. doi: 10.2217/fon.09.55.
Trastuzumab has become the standard of care in the management of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancers, both in the metastatic and adjuvant setting. Emerging data show continued efficacy of the drug even after disease progression in combination with chemotherapy. While cardiotoxicity is well recognized with trastuzumab, unusual pulmonary toxicities are becoming apparent. Cases that reflect the unusual efficacy and unusual toxicity of trastuzumab are reported.
曲妥珠单抗已成为人表皮生长因子受体 2（HER2）过表达乳腺癌管理中的标准治疗方法，无论是在转移性还是辅助治疗环境中。新出现的数据表明，即使在疾病进展后与化疗联合使用，该药物仍具有持续的疗效。虽然曲妥珠单抗的心脏毒性已得到充分认识，但不常见的肺部毒性也变得明显。报告了反映曲妥珠单抗不寻常疗效和不寻常毒性的病例。
